A BILL 
To provide additional funding under the Defense Production 
Act of 1950 related to medical supplies and equipment 
directly related to combating the COVID–19 pandemic, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘COVID–19 Medical 
4
Production Act’’. 
5
19:27 May 03, 2021
H1720
2 
•HR 1720 IH
SEC. 2. COVID–19 EMERGENCY MEDICAL SUPPLIES EN-
1
HANCEMENT. 
2
(a) SUPPORTING ENHANCED USE OF THE DEFENSE 
3
PRODUCTION ACT OF 1950.—In addition to funds other-
4
wise available, there is appropriated, out of amounts in 
5
the Treasury not otherwise appropriated, for fiscal year 
6
2021, $10,000,000,000, to remain available until Sep-
7
tember 30, 2025, to carry out titles I, III, and VII of the 
8
Defense Production Act of 1950 (50 U.S.C. 4501 et seq.) 
9
in accordance with subsection (b). 
10
(b) MEDICAL SUPPLIES AND EQUIPMENT.— 
11
(1) TESTING, PPE, VACCINES, AND OTHER MA-
12
TERIALS.—Except as provided in paragraph (2), 
13
amounts appropriated in subsection (a) shall be used 
14
for the purchase, production (including the construc-
15
tion, repair, and retrofitting of government-owned or 
16
private facilities as necessary), or distribution of 
17
medical supplies and equipment (including durable 
18
medical equipment) related to combating the 
19
COVID–19 pandemic, including— 
20
(A) in vitro diagnostic products (as defined 
21
in section 809.3(a) of title 21, Code of Federal 
22
Regulations) for the detection of SARS–CoV–2 
23
or the diagnosis of the virus that causes 
24
COVID–19, and the reagents and other mate-
25
rials necessary for producing, conducting, or 
26
23:13 May 06, 2021
H1720
3 
•HR 1720 IH
administering such products, and the machin-
1
ery, equipment, laboratory capacity, or other 
2
technology necessary to produce such products; 
3
(B) face masks and personal protective 
4
equipment, including face shields, nitrile gloves, 
5
N–95 filtering facepiece respirators, and any 
6
other masks or equipment (including durable 
7
medical equipment) determined by the Sec-
8
retary of Health and Human Services to be 
9
needed to respond to the COVID–19 pandemic, 
10
and the materials, machinery, additional manu-
11
facturing lines or facilities, or other technology 
12
necessary to produce such equipment; and 
13
(C) drugs and devices (as those terms are 
14
defined in the Federal Food, Drug, and Cos-
15
metic Act (21 U.S.C. 301 et seq.)) and biologi-
16
cal products (as that term is defined by section 
17
351 of the Public Health Service Act (42 
18
U.S.C. 262)) that are approved, cleared, li-
19
censed, or authorized under either of such Acts 
20
for use in treating or preventing COVID–19 
21
and symptoms related to COVID–19, and any 
22
materials, manufacturing machinery, additional 
23
manufacturing or fill-finish lines or facilities, 
24
technology, or equipment (including durable 
25
19:27 May 03, 2021
H1720
4 
•HR 1720 IH
medical equipment) necessary to produce or use 
1
such drugs, biological products, or devices (in-
2
cluding syringes, vials, or other supplies or 
3
equipment related to delivery, distribution, or 
4
administration). 
5
(2) RESPONDING
TO
PUBLIC
HEALTH
EMER-
6
GENCIES.—After September 30, 2022, amounts ap-
7
propriated in subsection (a) may be used for any ac-
8
tivity authorized by paragraph (1), or any other ac-
9
tivity that the Secretary of Health and Human Serv-
10
ices determines to be necessary, to meet critical pub-
11
lic health needs of the United States, with respect 
12
to any pathogen that the President has determined 
13
has the potential for creating a public health emer-
14
gency. 
15
(c) DELEGATION
AUTHORITY.—For purposes of 
16
using amounts appropriated in subsection (a), the Presi-
17
dent shall only delegate authority to— 
18
(1) with respect to any uses described under 
19
subsection (b), the Secretary of Health and Human 
20
Services; 
21
(2) with respect to uses described under sub-
22
section (b)(1), the head of any other agency respon-
23
sible for responding to the COVID–19 pandemic if 
24
the President determines that such delegation is im-
25
23:13 May 06, 2021
H1720
5 
•HR 1720 IH
portant to an effective response to such pandemic; 
1
and 
2
(3) with respect to uses described under sub-
3
section (b)(2), the head of any other agency respon-
4
sible for responding to any pathogen with the poten-
5
tial for creating a public health emergency if the 
6
President determines that such delegation is impor-
7
tant to an effective response to a public health emer-
8
gency that may be created by such pathogen. 
9
(d) APPLICATION OF LIMITATIONS UNDER THE DE-
10
FENSE PRODUCTION ACT OF 1950.—The requirements 
11
described in section 304(e) of the Defense Production Act 
12
of 1950 (50 U.S.C. 4534(e)) shall not apply to the funds 
13
appropriated in subsection (a) until September 30, 2025. 
14
Æ 
19:27 May 03, 2021
H1720
